[ad_1]
Novavax’s two-dose, protein-based vaccine was approved to be used this week by European Union regulators and the World Well being Group. It has beforehand been accredited by international locations together with Indonesia and the Philippines however not the US.
Novavax mentioned that receiving a further booster dose of Novavax’s vaccine additional elevated folks’s immune response to Omicron. The information was taken from Novavax’s ongoing research of its vaccine’s effectiveness in adolescents and as a booster.
“We’re inspired that boosted responses in opposition to all variants have been akin to these related to excessive vaccine efficacy in our Section 3 scientific trials,” mentioned Gregory M. Glenn, Novavax’s president of analysis and improvement.
Different COVID-19 vaccine producers, together with Pfizer Inc. and Moderna Inc., additionally enhance immune responses to Omicron, early information from these corporations has proven. Resistance in all instances is stronger in individuals who have obtained a further booster dose.
Novavax is engaged on growing an Omicron-specific vaccine and mentioned Wednesday it expects to start manufacturing doses of the variant-specific shot in January.
The drugmaker will begin delivery vaccines to the EU’s 27 member states in January as a part of its deal to produce as much as 200 million doses.
The corporate may even start shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 photographs to poorer international locations. Novavax and its companion, Serum Institute of India, have agreed to ship COVAX greater than 1.1 billion doses of Novavax’s vaccine.
[ad_2]
Source link